Novavax expands COVID-19 vaccine trial to include adolescents

By The Science Advisory Board staff writers

May 3, 2021 -- Novavax has started a pediatric expansion of its phase III clinical trial for NVX-CoV2373, the company's recombinant protein vaccine candidate against COVID-19.

The expansion will evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 in up to 3,000 adolescents ages 12-17 across 75 sites in the U.S., as part of its U.S./Mexico-based Prevent-19 trial.

Participants will randomly receive either the vaccine or placebo in two doses, administered 21 days apart. Two-thirds of participants will receive intramuscular injections for the vaccine while the other third will receive a placebo.

The company has planned for a blinded crossover to take place six months after an initial set of vaccinations to ensure that all participants receive an active vaccine. Participants will be monitored for safety for up to two years following a final dose.

Novavax COVID-19 vaccine to be included in combo vaccine study
Novavax announced it will participate in a newly expanded phase II trial to study NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate. The...
GSK to provide services for Novavax's COVID-19 vaccine in the U.K.
GlaxoSmithKline (GSK) has signed an agreement in principle to support manufacturing of up to 60 million doses of Novavax's NVX-CoV2373 COVID-19 vaccine...
Novavax confirms efficacy against U.K., South African SARS-CoV-2 strains
Novavax's SARS-CoV-2 vaccine candidate NVX-CoV2373 has a 96.4% efficacy against mild, moderate, and severe disease caused by the original COVID-19 strain,...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter